Antineoplastic Agents Market
Antineoplastic Agents Market Analysis, By Product (Chemotherapeutic Agents, Biological/Immunotherapeutic Agents, Personalized Medicines, Hormonal Agents, Others), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers), & Region - Global Market Insights 2023-2033
Analysis of Antineoplastic Agents Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Antineoplastic Agents Market Growth Outlook 2023-2033
Sales of antineoplastic agents are expected to be valued at US$ 126.71 billion in 2023, with the market expected to reach a valuation of US$ 286.49 billion by the end of 2033.
Global demand for chemotherapeutic agents and biological/immunotherapeutic agents is predicted to increase at CAGRs of 8% and 9% during the next 10 years, respectively.
Anti-neoplastic drugs are classified into chemotherapeutic agents, biological/immunotherapeutic agents, personalized medicines, alkylating and alkylating-like agents, hormonal agents, and miscellaneous agents.
Demand for biological/immunotherapeutic agents is increasing rapidly this can primarily be attributed to the recent outbreak of coronavirus and the increasing focus of several medical experts on nanotechnology to provide developed treatments to target patients.
To treat cancer while sparing healthy cells, biological therapy utilizes the immune system of the patient. Monoclonal antibodies, for example, are a type of biological medicinal therapy that works by either increasing cell death or slowing the growth of cancer.
Innovative research has led to the development of biological pharmaceuticals, which can result in novel treatments that give patients a variety of new therapy options. Additionally, improved genetic and molecular understanding has opened the door for several cutting-edge therapies.
- The World Health Organization 2021 estimates that non-communicable diseases are accountable for 41 million fatalities annually. Seen between the ages of 30 and 69, more than 15 million individuals worldwide pass away annually due to non-communicable diseases. These "premature" deaths account for about 85% of all deaths in poor and developing nations.
- The majority of fatalities from non-communicable diseases are caused by cardiovascular disorders (17.9 million per year), followed by cancer (9.3 million per year), respiratory conditions (4.1 million per year), and diabetes (1.5 million per year). Thus, the demand for biological agents is increasing due to the rising prevalence of chronic illnesses.
- The University of Texas at Austin's College of Natural Sciences and Cockrell School of Engineering is leading a research initiative called the TXBio Pilot Grant Program that concentrates on the invention, fast development, and clinical translation of biological therapies created all through the university (UT Austin). TXBio (Texas Biologics) is backed by charitable donations that are being used to enhance UT Austin's infrastructure and intellectual climate regarding the development and translation of biologics.
- The FDA approved a biologics license application (BLA) for tezepelumab, a potential first-in-class treatment for severe asthma, from Amgen's partner AstraZeneca in May 2021.
Thus, rising investments in R&D by top players and several end users are also driving sales growth.
Cytotoxic or anti-neoplastic drugs prevent the development and spread of tumours. They enter the body of the individual and eliminate the malignant cells. Along with being used in radiotherapies, surgeries, and immunotherapies for several metastatic tumours, these medications are used to treat a wide range of cancers.
With fresh cases of neoplasms being reported all over the world, the antineoplastic agents market is expected to grow quickly.
Over the coming years, the market for anti-neoplastic agents is expected to expand due to the rising demand for affordable treatments for treating neoplasms.
Report Attributes |
Details |
|
Market Size in 2023 |
US$ 126.71 Billion |
|
Forecasted Market Value (2033F) |
US$ 286.49 Billion |
|
Global Market Growth Rate (2023-2033) |
8.5% CAGR |
|
China Market Growth Rate (2023-2033) |
12% CAGR |
|
Japan Market Growth Rate (2023-2033) |
5% CAGR |
|
Germany Market Growth Rate (2023-2033) |
6% CAGR |
|
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
What is Driving the Sales of Antineoplastic Agents?
“Increasing Senior Population Suffering from Chronic Diseases”
Patients with lung, bone, and other cancers regularly utilise analgesics including acetaminophen, morphine, and nonsteroidal anti-inflammatory drugs. The cost of spending on cancer-fighting medications has significantly increased as more individuals are diagnosed with cancer. Therefore, the rising cases of cancer cases are predicted to fuel anti-neoplastic agents market growth.
The size of the senior population is increasing rapidly when compared to the younger population.
- According to recent studies, there will be 95 million more Americans 65 and older by 2060 than there are now, raising the percentage of the population that is 65 and older from 16% to around 23%.
The ageing population is more prone to several chronic disorders, which is therefore expected to increase demand for cancer prevention drugs, fueling the growth of the anti-neoplastic agents market.
“Growing Investments in R&D by Leading Anti-Neoplastic Agent Companies to Develop Improved Drug Therapies”
Cancer patients are treated to cure the disease and improve health & quality of life. Immune cells play a vital role in tumour progression. Therefore, activating immune responses against malignancies is a desirable preventative and therapeutic approach.
Therefore, top market players are investing highly in immunotherapy research and development to treat a variety of cancers.
- For instance, in March 2019, the National Cancer Center Japan and FUJIFILM Corporation collaboratively announced the beginning of a research project for breakthrough cancer immunotherapy utilizing a liposome formulation.
Due to its success in terms of effective treatment that leads to better patient outcomes, immunotherapy is more widely used nowadays. As a result, this is boosting the demand for anti-neoplastic agents.
“Rising Worldwide Prevalence of Cancer Disorders”
The incidence of cancer has climbed globally, overtaking cardiovascular diseases as the 2nd largest cause of death. This is caused by environmental variables such as high cigarette use, altered dietary habits, urbanisation, and prolonged post-reproductive life.
For instance, the World Health Organization (WHO) estimates that there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018.
Therefore, it is anticipated that throughout the projection period, the rising incidence of cancer diseases will increase the demand for anti-neoplastic agents globally.
“Oral Chemotherapy Gaining Traction”
Cancer can also be treated with oral chemotherapy, where the oral route for medication is used. Oral chemotherapy medications come in a variety of forms, including tablets, pills, and liquid. Oral chemotherapy's primary function is to both kill and retard the growth of cancer cells. Oral chemotherapy can also be administered at home.
Cancer patients who prefer oral chemotherapy must adhere to a few precautions and recommendations. Patients can also get oral chemotherapy using infusion pumps. The main aspect of the enormous growth of the oral chemotherapy market is the rising cases of cancer ailments worldwide.
Why Can Affect Production of Antineoplastic Agents?
“Strict Rules for Drug Approvals & High Cost of Production”
According to regulatory agency rules and regulations, including that from the US FDA and other organisations, anticancer drugs are developed and sold. For the product launches to be approved, manufacturers of anti-neoplastic agents must submit comprehensive clinical data that demonstrate the product's efficacy and safety.
These approval processes are frequently time-consuming and demand a large financial investment from the major businesses, which directly affects the price of the drugs they produce. The high cost of production affects the product's final price. Because of this, the demand for antineoplastic antibiotics is limited by financial toxicity, placing a heavy financial burden on cancer sufferers.
Which Potential Opportunities Await New Market Players?
“Use of Smart Technologies Will Generate New Opportunities in Antineoplastic Agents Market”
The new entrants are producing several anticancer medications and are using smart technologies to increase their field productivity and efficiency. This move is going to help start-ups to gain a profitable client base and own a strong market position.
Some of the new businesses in the antineoplastic agents industry are Voxtur Bio Ltd., RS Research, and others.
Following are some recent developments in the start-up section
- Particularly since the coronavirus outbreak, biotechnology businesses have drawn increasing attention on a global scale. Numerous Turkish organizations, notably Türk Telekom, have health start-up companies on their radar.
- Virasoft, a company that specializes in smart pathology technologies, has received funding from one of the top information and communication technology businesses TT Ventures in the nation. All of the private academic hospitals, three public hospitals, and 20 more private hospitals in Istanbul currently use Virasoft's Digital Pathology technologies.
- With Türk Telekom's funding, municipal hospitals should also be able to use Virasoft's service as part of the government's initiative to expand the number of beds available and address the physician shortage in densely populated areas.
- Nano-drugs are garnering interest in the fight against cancer, similar to how the vaccination did. Sena Nomak and Rana Sanyal formed the biotechnology start-up RS Research in 2015, and the company is getting ready to introduce the first Turkish nanotechnology medication. The next-generation pharmaceuticals business RS Research creates unique nanomedicines based on cutting-edge drug delivery systems for therapies to cure cancer patients.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
What is Supporting the Increasing Sales of Antineoplastic Agents in the U.S.?
“Rising Cases of Cancer in the United States”
Demand for anti-neoplastic pharmaceutical drugs in the U.S. is expanding as a result of quickly increasing cases of cancer, rising healthcare expenditures, high rates of cancer diagnostic testing, accessibility to multiple cutting-edge cancer treatments, and a sizable presence of top manufacturers of anti-neoplastic agents.
One of the main factors driving the sales of antineoplastic agents in the United States is the presence of an established R&D infrastructure and growing awareness of cancer and related treatment. Growing public awareness of the advantages of early cancer detection has encouraged American-based businesses to spend heavily on the creation of medications for targeted therapy.
Why is the Asia Pacific Region Attracting Several Antineoplastic Drug Producers?
“Asian Countries Highly Preferred by Manufacturers of Antineoplastic Agents to Build Production Units”
Japan, South Korea, India, and China are major marketplaces in the Asia Pacific region. Major pharmaceutical companies have established units for manufacturing and R&D in the Asia Pacific region as a result of the rapid rise in worldwide antineoplastic drug demand and the quickly increasing healthcare industry in the region.
Regional market growth is expected to be boosted by efforts made by various organizations to aware the public regarding several chronic diseases and raise funds for needy patients living with target illnesses.
The quick increase is probably due to a rapidly ageing population with several disorders, changing lifestyles, and socioeconomic changes. Lung, stomach, and liver cancers are among the most prevalent disorders.
South Korea experienced a high rate of fatalities due to cancer in 2021, among which lung cancer ranked first followed by liver and colorectal. While, breast, prostate, colorectal (big bowel), stomach, and lung cancers are the most prevalent types of cancer disorders in Japan.
- According to several studies, more than 90 thousand cases of breast cancer were seen in Japan in 2021.
Sales of antineoplastic agents in Japan are predicted to increase at a CAGR of 5% from 2023 to 2033. As a result, high investments are made in healthcare to build cutting-edge R&D facilities for creating high-quality oncology diagnostics, which is likely to fuel the demand for cancer immunotherapies in the Asia Pacific region through the forecast period.
How is Europe’s Antineoplastic Agents Market Developing?
“Growing Number of R&D Activities in Anticancer Drug Development”
The U.K. market for antineoplastic agent suppliers and manufacturers is expanding as biological research to create efficient cancer diagnostics intensifies.
- Since January 2021, several studies have been suggested to determine potential connections between serine consumption and the formation of cancer cells, according to Cancer Research UK.
As a result of some cancer cells' ability to produce their serine, particularly in patients with KRAS mutations, results to date have been inconsistent. Fortunately, scientists believe that further study will lead to a standardised result, increasing the likelihood that different cancer screening strategies will be used in the future.
- In the last five years, there were over 2 million cases of cancer ailments in Germany, with over 600,000 new cases and 252 thousand fatalities, according to Globocan 2020.
The nation's increased cancer rate has been mostly attributable to binge drinking and heavy smoking.
Strong institutional frameworks, including the German Cancer Consortium and important Comprehensive Cancer Centers (CCCs) headquartered at University Medical Centers, are crucial to advancing cancer research across the nation. Top antineoplastic agent producers around the nation are being drawn in by this increased support.
Category-wise Analysis
Why Do Hospitals Make High Use of Antineoplastic Drugs?
“Hospitals Hold Dominant Position in Providing Antineoplastic Therapies”
The preferred medical settings for cancer treatment are still hospitals since these facilities have the most cutting-edge technologies for accurate diagnosis and treatment. The high adoption of cutting-edge therapeutics, diagnoses, and medical technologies, supported by private and public funding, raises the standard of Medicare provided by hospitals. By 2033, hospitals are anticipated to hold a strong market share for antineoplastic drugs.
It is anticipated that a larger patient base will choose clinic-based healthcare due to the relatively short wait times and convenience of scheduling appointments. The exponential acceptance of cancer treatments in clinics is being driven by the steadily increasing demand for high-quality cancer therapeutics, which is encouraging clinicians to concentrate on providing improved antineoplastic therapies to patients.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Competitive Landscape
Large-scale clinical trials that confirm the effectiveness of various antineoplastic therapeutic techniques, such as vaccinations and oral medications, are being conducted by prominent market participants for financial gain. Players are also investing more in research studies to identify regional patterns in cancer prevalence.
- ChemoCentryx, Inc., a biopharmaceutical business focused on orally delivered medicines to treat autoimmune diseases, inflammatory disorders, and cancer, was acquired by Amgen in October 2022.
- ImmunityBio, Inc. and NantKwest, Inc. merged on March 20, 2021, to form a preeminent late-stage cell therapy and immunotherapy company with a focus on cancer and infectious diseases.
Key Segments of Antineoplastic Agents Industry Research
-
By Product :
- Chemotherapeutic Agents
- Biological/Immunotherapeutic Agents
- Personalized Medicines
- Alkylating and Alkylating-like Agents
- Hormonal Agents, Miscellaneous Agents
-
By End User :
- Hospitals
- Clinics
- Cancer Rehabilitation Centers
- Ambulatory Surgical Centers
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product modifications /Innovation/p> 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Product USPs /Technology 4.4. List of Manufacturers and Providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New Product launches 5.2.2. Cost of Products 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as Compared to 2008 Economic analysis 6.4. COVID19 and Impact Analysis 6.4.1. Revenue By Product 6.4.2. Revenue By End User 6.4.3. Revenue By Country 6.5. 2022 Market Scenario 6.6. Quarter by Quarter Forecast 6.7. Projected Recovery Quarter 7. Global Market Volume (Units) Analysis 2018-2022 and Forecast, 2023-2033 7.1. Historical Market Volume (Units) Analysis, 2018-2022 7.2. Current and Future Market Volume (Units) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Analysis 8.1. Regional Pricing Analysis By Product 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Market Value Analysis 2018–2022 and Forecast, 2023-2033 9.1. Historical Market Value (US$ Mn) Analysis, 2018–2022 9.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2018–2022 and Forecast 2023-2033, by Product 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2018–2022 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2023-2033 10.3.1. Chemotherapeutic Agents 10.3.2. Biological/Immunotherapeutic Agents 10.3.3. Personalized Medicines 10.3.4. Alkylating and Alkylating-like Agents 10.3.5. Hormonal Agents, Miscellaneous Agents 10.4. Market Attractiveness Analysis By Product 11. Global Market Analysis 2018–2022 and Forecast 2023-2033, by End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By End User , 2018–2022 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User , 2023-2033 11.3.1. Hospitals 11.3.2. Clinics 11.3.3. Cancer Rehabilitation Centers 11.3.4. Ambulatory Surgical Centers 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2018–2022 and Forecast 2023-2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2018–2022 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018–2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Product 13.3.3. By End User 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Market Analysis 2018–2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Product 14.3.3. By End User 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018–2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Product 15.3.3. By End User 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Market Analysis 2018–2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Product 16.3.3. By End User 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Market Analysis 2018–2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Product 17.3.3. By End User 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Market Analysis 2018–2022 and Forecast 2023-2033 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Product 18.3.3. By End User 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Market Analysis 2018–2022 and Forecast 2023-2033 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018–2022 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Product 19.3.3. By End User 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Market Analysis 2018–2022 and Forecast 2023-2033 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Market Analysis 20.2.1. By Product 20.2.2. By End User 20.3. Canada Market Analysis 20.3.1. By Product 20.3.2. By End User 20.4. Mexico Market Analysis 20.4.1. By Product 20.4.2. By End User 20.5. Brazil Market Analysis 20.5.1. By Product 20.5.2. By End User 20.6. U.K. Market Analysis 20.6.1. By Product 20.6.2. By End User 20.7. Germany Market Analysis 20.7.1. By Product 20.7.2. By End User 20.8. France Market Analysis 20.8.1. By Product 20.8.2. By End User 20.9. Italy Market Analysis 20.9.1. By Product 20.9.2. By End User 20.10. Spain Market Analysis 20.10.1. By Product 20.10.2. By End User 20.11. BENELUX Market Analysis 20.11.1. By Product 20.11.2. By End User 20.12. Russia Market Analysis 20.12.1. By Product 20.12.2. By End User 20.13. China Market Analysis 20.13.1. By Product 20.13.2. By End User 20.14. Japan Market Analysis 20.14.1. By Product 20.14.2. By End User 20.15. South Korea Market Analysis 20.15.1. By Product 20.15.2. By End User 20.16. India Market Analysis 20.16.1. By Product 20.16.2. By End User 20.17. ASEAN Market Analysis 20.17.1. By Product 20.17.2. By End User 20.18. Australia Market Analysis 20.18.1. By Product 20.18.2. By End User 20.19. New Zealand Market Analysis 20.19.1. By Product 20.19.2. By End User 20.20. GCC Countries Market Analysis 20.20.1. By Product 20.20.2. By End User 20.21. Turkey Market Analysis 20.21.1. By Product 20.21.2. By End User 20.22. South Africa Market Analysis 20.22.1. By Product 20.22.2. By End User 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Jiangsu Haosen Pharmaceutical Group 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.2. Abraxis 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.3. AstraZeneca 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.4. Baekdu Mountain Pharmaceutical 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.5. Baida Pharmaceutical 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.6. Bayer 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.7. Biogen Idec 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Profitability by Market Segments (Product/Channel/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Strategy Overview 22.3.8. BMS 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Profitability by Market Segments (Product/Channel/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Strategy Overview 22.3.9. Celgene 22.3.9.1. Overview 22.3.9.2. Product Portfolio 22.3.9.3. Profitability by Market Segments (Product/Channel/Region) 22.3.9.4. Sales Footprint 22.3.9.5. Strategy Overview 22.3.10. CTTQ 22.3.10.1. Overview 22.3.10.2. Product Portfolio 22.3.10.3. Profitability by Market Segments (Product/Channel/Region) 22.3.10.4. Sales Footprint 22.3.10.5. Strategy Overview 22.3.11. Eisai 22.3.11.1. Overview 22.3.11.2. Product Portfolio 22.3.11.3. Profitability by Market Segments (Product/Channel/Region) 22.3.11.4. Sales Footprint 22.3.11.5. Strategy Overview 22.3.12. Gilead 22.3.12.1. Overview 22.3.12.2. Product Portfolio 22.3.12.3. Profitability by Market Segments (Product/Channel/Region) 22.3.12.4. Sales Footprint 22.3.12.5. Strategy Overview 22.3.13. Hainan Chang`an International Pharmaceutical 22.3.13.1. Overview 22.3.13.2. Product Portfolio 22.3.13.3. Profitability by Market Segments (Product/Channel/Region) 22.3.13.4. Sales Footprint 22.3.13.5. Strategy Overview 22.3.14. Jiangsu Hengrui Pharmaceutical 22.3.14.1. Overview 22.3.14.2. Product Portfolio 22.3.14.3. Profitability by Market Segments (Product/Channel/Region) 22.3.14.4. Sales Footprint 22.3.14.5. Strategy Overview 22.3.15. Johnson and Johnson 22.3.15.1. Overview 22.3.15.2. Product Portfolio 22.3.15.3. Profitability by Market Segments (Product/Channel/Region) 22.3.15.4. Sales Footprint 22.3.15.5. Strategy Overview 22.3.16. Liaoning Novino Pharmaceutical 22.3.16.1. Overview 22.3.16.2. Product Portfolio 22.3.16.3. Profitability by Market Segments (Product/Channel/Region) 22.3.16.4. Sales Footprint 22.3.16.5. Strategy Overview 22.3.17. Lilly 22.3.17.1. Overview 22.3.17.2. Product Portfolio 22.3.17.3. Profitability by Market Segments (Product/Channel/Region) 22.3.17.4. Sales Footprint 22.3.17.5. Strategy Overview 22.3.18. Maanshan Fengyuan Pharmaceutical 22.3.18.1. Overview 22.3.18.2. Product Portfolio 22.3.18.3. Profitability by Market Segments (Product/Channel/Region) 22.3.18.4. Sales Footprint 22.3.18.5. Strategy Overview 22.3.19. Meiluo Pharmaceutical 22.3.19.1. Overview 22.3.19.2. Product Portfolio 22.3.19.3. Profitability by Market Segments (Product/Channel/Region) 22.3.19.4. Sales Footprint 22.3.19.5. Strategy Overview 22.3.20. MSD 22.3.20.1. Overview 22.3.20.2. Product Portfolio 22.3.20.3. Profitability by Market Segments (Product/Channel/Region) 22.3.20.4. Sales Footprint 22.3.20.5. Strategy Overview 22.3.21. Novartis 22.3.21.1. Overview 22.3.21.2. Product Portfolio 22.3.21.3. Profitability by Market Segments (Product/Channel/Region) 22.3.21.4. Sales Footprint 22.3.21.5. Strategy Overview 22.3.22. Pfizer 22.3.22.1. Overview 22.3.22.2. Product Portfolio 22.3.22.3. Profitability by Market Segments (Product/Channel/Region) 22.3.22.4. Sales Footprint 22.3.22.5. Strategy Overview 22.3.23. Qilu Pharmaceutical 22.3.23.1. Overview 22.3.23.2. Product Portfolio 22.3.23.3. Profitability by Market Segments (Product/Channel/Region) 22.3.23.4. Sales Footprint 22.3.23.5. Strategy Overview 22.3.24. Roche 22.3.24.1. Overview 22.3.24.2. Product Portfolio 22.3.24.3. Profitability by Market Segments (Product/Channel/Region) 22.3.24.4. Sales Footprint 22.3.24.5. Strategy Overview 22.3.25. Sanofi 22.3.25.1. Overview 22.3.25.2. Product Portfolio 22.3.25.3. Profitability by Market Segments (Product/Channel/Region) 22.3.25.4. Sales Footprint 22.3.25.5. Strategy Overview 22.3.26. Shandong Luoxin Pharmaceutical Group 22.3.26.1. Overview 22.3.26.2. Product Portfolio 22.3.26.3. Profitability by Market Segments (Product/Channel/Region) 22.3.26.4. Sales Footprint 22.3.26.5. Strategy Overview 22.3.27. Shandong Lvye Pharmaceutical 22.3.27.1. Overview 22.3.27.2. Product Portfolio 22.3.27.3. Profitability by Market Segments (Product/Channel/Region) 22.3.27.4. Sales Footprint 22.3.27.5. Strategy Overview 22.3.28. Shandong New Era Pharmaceutical 22.3.28.1. Overview 22.3.28.2. Product Portfolio 22.3.28.3. Profitability by Market Segments (Product/Channel/Region) 22.3.28.4. Sales Footprint 22.3.28.5. Strategy Overview 22.3.29. Sinopharm 22.3.29.1. Overview 22.3.29.2. Product Portfolio 22.3.29.3. Profitability by Market Segments (Product/Channel/Region) 22.3.29.4. Sales Footprint 22.3.29.5. Strategy Overview 22.3.30. Tesaro (GSK) 22.3.30.1. Overview 22.3.30.2. Product Portfolio 22.3.30.3. Profitability by Market Segments (Product/Channel/Region) 22.3.30.4. Sales Footprint 22.3.30.5. Strategy Overview 22.3.31. Teva 22.3.31.1. Overview 22.3.31.2. Product Portfolio 22.3.31.3. Profitability by Market Segments (Product/Channel/Region) 22.3.31.4. Sales Footprint 22.3.31.5. Strategy Overview 22.3.32. Wto-Day Order Pharmaceutical 22.3.32.1. Overview 22.3.32.2. Product Portfolio 22.3.32.3. Profitability by Market Segments (Product/Channel/Region) 22.3.32.4. Sales Footprint 22.3.32.5. Strategy Overview 22.3.33. Zhejiang Kanglaite Pharmaceutical 22.3.33.1. Overview 22.3.33.2. Product Portfolio 22.3.33.3. Profitability by Market Segments (Product/Channel/Region) 22.3.33.4. Sales Footprint 22.3.33.5. Strategy Overview 22.3.34. Zhejiang Yatai Pharmaceutical 22.3.34.1. Overview 22.3.34.2. Product Portfolio 22.3.34.3. Profitability by Market Segments (Product/Channel/Region) 22.3.34.4. Sales Footprint 22.3.34.5. Strategy Overview 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2018–2033, By Product
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 08: Latin America Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 11: Europe Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 14: South Asia Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 17: East Asia Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 20: Oceania Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2018-2022 and Forecast 2022–2032, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By Product
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018–2033, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2018-2022
Figure 02: Global Market Volume Forecast (in 000' Units), 2023-2033
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2022
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2022
Figure 05: Global Market Value Analysis (US$ Mn), 2018-2022
Figure 06: Global Market Value Forecast (US$ Mn), 2023-2033
Figure 07: Global Market Absolute $ Opportunity, 2023-2033
Figure 08: Global Market Share Analysis (%), By Product, 2023-2033
Figure 09: Global Market Y-o-Y Analysis (%), By Product, 2023-2033
Figure 10: Global Market Attractiveness Analysis by Product, 2023-2033
Figure 11: Global Market Share Analysis (%), By End User, 2023-2033
Figure 12: Global Market Y-o-Y Analysis (%), By End User, 2023-2033
Figure 13: Global Market Attractiveness Analysis by End User, 2023-2033
Figure 14: Global Market Share Analysis (%), By Region, 2023-2033
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2023-2033
Figure 16: Global Market Attractiveness Analysis by Region, 2023-2033
Figure 17: North America Market Value Share, By Product, 2022 (E)
Figure 18: North America Market Value Share, By End User, 2022 (E)
Figure 19: North America Market Value Share, By Country, 2022 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2018-2022
Figure 21: North America Market Value Forecast (US$ Mn), 2023-2033
Figure 22: North America Market Attractiveness Analysis by Product, 2023-2033
Figure 23: North America Market Attractiveness Analysis by End User, 2023-2033
Figure 24: North America Market Attractiveness Analysis by Country, 2023-2033
Figure 25: Latin America Market Value Share, By Product, 2022 (E)
Figure 26: Latin America Market Value Share, By End User, 2022 (E)
Figure 27: Latin America Market Value Share, By Country, 2022 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2018-2022
Figure 29: Latin America Market Value Forecast (US$ Mn), 2023-2033
Figure 30: Latin America Market Attractiveness Analysis by Product, 2023-2033
Figure 31: Latin America Market Attractiveness Analysis by End User, 2023-2033
Figure 32: Latin America Market Attractiveness Analysis by Country, 2023-2033
Figure 33: Europe Market Value Share, By Product, 2022 (E)
Figure 34: Europe Market Value Share, By End User, 2022 (E)
Figure 35: Europe Market Value Share, By Country, 2022 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2018-2022
Figure 37: Europe Market Value Forecast (US$ Mn), 2023-2033
Figure 38: Europe Market Attractiveness Analysis by Product, 2023-2033
Figure 39: Europe Market Attractiveness Analysis by End User, 2023-2033
Figure 40: Europe Market Attractiveness Analysis by Country, 2023-2033
Figure 41: South Asia Market Value Share, By Product, 2022 (E)
Figure 42: South Asia Market Value Share, By End User, 2022 (E)
Figure 43: South Asia Market Value Share, By Country, 2022 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2018-2022
Figure 45: South Asia Market Value Forecast (US$ Mn), 2023-2033
Figure 46: South Asia Market Attractiveness Analysis by Product, 2023-2033
Figure 47: South Asia Market Attractiveness Analysis by End User, 2023-2033
Figure 48: South Asia Market Attractiveness Analysis by Country, 2023-2033
Figure 49: East Asia Market Value Share, By Product, 2022 (E)
Figure 50: East Asia Market Value Share, By End User, 2022 (E)
Figure 51: East Asia Market Value Share, By Country, 2022 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2018-2022
Figure 53: East Asia Market Value Forecast (US$ Mn), 2023-2033
Figure 54: East Asia Market Attractiveness Analysis by Product, 2023-2033
Figure 55: East Asia Market Attractiveness Analysis by End User, 2023-2033
Figure 56: East Asia Market Attractiveness Analysis by Country, 2023-2033
Figure 57: Oceania Market Value Share, By Product, 2022 (E)
Figure 58: Oceania Market Value Share, By End User, 2022 (E)
Figure 59: Oceania Market Value Share, By Country, 2022 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2018-2022
Figure 61: Oceania Market Value Forecast (US$ Mn), 2023-2033
Figure 62: Oceania Market Attractiveness Analysis by Product, 2023-2033
Figure 63: Oceania Market Attractiveness Analysis by End User, 2023-2033
Figure 64: Oceania Market Attractiveness Analysis by Country, 2023-2033
Figure 65: Middle East and Africa Market Value Share, By Product, 2022 (E)
Figure 66: Middle East and Africa Market Value Share, By End User, 2022 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2022 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2018-2022
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2023-2033
Figure 70: Middle East and Africa Market Attractiveness Analysis by Product, 2023-2033
Figure 71: Middle East and Africa Market Attractiveness Analysis by End User, 2023-2033
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2023-2033
Figure 73: U. S. Market Value Analysis (US$ Mn), 2023 & 2033
Figure 74: U. S. Market Value Share, By Product, 2022 (E)
Figure 75: U. S. Market Value Share, By End User, 2022 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2023 & 2033
Figure 77: Canada Market Value Share, By Product, 2022 (E)
Figure 78: Canada Market Value Share, By End User, 2022 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2023 & 2033
Figure 80: Mexico Market Value Share, By Product, 2022 (E)
Figure 81: Mexico Market Value Share, By End User, 2022 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2023 & 2033
Figure 83: Brazil Market Value Share, By Product, 2022 (E)
Figure 84: Brazil Market Value Share, By End User, 2022 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2023 & 2033
Figure 86: U. K. Market Value Share, By Product, 2022 (E)
Figure 87: U. K. Market Value Share, By End User, 2022 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2023 & 2033
Figure 89: Germany Market Value Share, By Product, 2022 (E)
Figure 90: Germany Market Value Share, By End User, 2022 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2023 & 2033
Figure 92: France Market Value Share, By Product, 2022 (E)
Figure 93: France Market Value Share, By End User, 2022 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2023 & 2033
Figure 95: Italy Market Value Share, By Product, 2022 (E)
Figure 96: Italy Market Value Share, By End User, 2022 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2023 & 2033
Figure 98: Spain Market Value Share, By Product, 2022 (E)
Figure 99: Spain Market Value Share, By End User, 2022 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2023 & 2033
Figure 101: Russia Market Value Share, By Product, 2022 (E)
Figure 102: Russia Market Value Share, By End User, 2022 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2023 & 2033
Figure 104: China Market Value Share, By Product, 2022 (E)
Figure 105: China Market Value Share, By End User, 2022 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2023 & 2033
Figure 107: Japan Market Value Share, By Product, 2022 (E)
Figure 108: Japan Market Value Share, By End User, 2022 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2023 & 2033
Figure 110: South Korea Market Value Share, By Product, 2022 (E)
Figure 111: South Korea Market Value Share, By End User, 2022 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2023 & 2033
Figure 113: India Market Value Share, By Product, 2022 (E)
Figure 114: India Market Value Share, By End User, 2022 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2023 & 2033
Figure 116: ASEAN Market Value Share, By Product, 2022 (E)
Figure 117: ASEAN Market Value Share, By End User, 2022 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2023 & 2033
Figure 119: Australia Market Value Share, By Product, 2022 (E)
Figure 120: Australia Market Value Share, By End User, 2022 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2023 & 2033
Figure 122: New Zealand Market Value Share, By Product, 2022 (E)
Figure 123: New Zealand Market Value Share, By End User, 2022 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2023 & 2033
Figure 125: GCC Countries Market Value Share, By Product, 2022 (E)
Figure 126: GCC Countries Market Value Share, By End User, 2022 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2023 & 2033
Figure 128: Turkey Market Value Share, By Product, 2022 (E)
Figure 129: Turkey Market Value Share, By End User, 2022 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2023 & 2033
Figure 131: South Africa Market Value Share, By Product, 2022 (E)
Figure 132: South Africa Market Value Share, By End User, 2022 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the estimated value for the global anti-neoplastic agents market?
Global anti-neoplastic agent sales are valued at US$ 126.71 billion in 2023.
How big is the anti-neoplastic agents market?
Global demand for anti-neoplastic agents is expected to increase at a CAGR of 8.5% and reach US$ 286.49 billion by 2033.
Which region led the global anti-neoplastic agents market?
North America holds a dominating position in the global market.
What are the key driving factors for the growth of the anti-neoplastic agents market?
Rising investments by multinational companies in cancer research due to the increasing number of cancer cases are driving the market growth.
Who are the key companies in the global market for anti-neoplastic agents?
Some of the key players in the antineoplastic agents market are Bayer, Sanofi, and ChemoCentryx, Inc.
Antineoplastic Agents Market